Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species
Data indicate that high type 5 phosphodiesterase (PDE5) expression in glioblastoma multiforme (GBM) cells significantly correlated with longer overall survival of patients.
the relationship between PDE5A polymorphisms, diabetes, and the efficacy of sildenafil treatment.The response to sildenafil treatment depends on polymorphisms in the PDE5A gene and the glycemic status of the patients.
Study showed that past attempts to quantify PDE5 mRNA were flawed due to the use of incorrect primers, and that when correct primers are used, PDE5 mRNA is detectable in human brain tissue; that PDE5 protein exists in human brain by western blot and ELISA; and performed immunohistochemistry and demonstrate that PDE5 is present in human neurons.
Our data showed a significant and previously undocumented upregulation of PDE5 in both rat and human BPH (show GLI3 ELISA Kits).
Overexpression of PDE5 in papillary thyroid carcinomas.
cGMP PDE (show ALDH7A1 ELISA Kits) isozymes, PDE5 and 10, are elevated in colon tumor cells compared with normal colonocytes, and inhibitors and siRNAs can selectively suppress colon tumor cell growth
Results show that Ser102 and Ser104 may influence the conformational flexibility of PDE5A, which may in turn influence phosphorylation status, allosteric regulation by cGMP or other as yet unknown regulatory mechanisms for PDE5A.
PDE5A appears to jointly influence amygdala volume and emotion recognition performance.
inhibition of PDE5 can counteract apoptosis during aging by modulating proand antiapoptotic molecules and the APP (show APP ELISA Kits) pathway.
Myocardial PDE5 expression is increased in the hearts of humans and mice with chronic pressure overload.
Report expression of Pde5a1/2/3 in cardiac myocytes and suggest role in induction of cardiac hypertrophy.
Upon S-nitrosylation, PDE5 exhibits reduced activity and degradation via the ubiquitin-proteasome system.
Short-term hemolysis is sufficient to establish a priapism phenotype and results in loss of erectile function. PDE5I treatment ameliorates priapism, in part, because of restored NO balance with decreased ROS (show ROS1 ELISA Kits) generation and increased PDE5 activity.
Addition of sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, in the drinking water had a small effect in reducing myocyte hypertrophy in wild type mice and no effect in betaRM mice.
findings reveal that excess adenosine-mediated ADORA2B (show ADORA2B ELISA Kits) signaling underlies reduced penile PDE (show TWIST1 ELISA Kits) activity by decreasing PDE5 gene expression in a HIF-1alpha (show HIF1A ELISA Kits)-dependent manner
Findings suggest that continuous, long-term treatment with PDE5 inhibitors reverses eNOS (show NOS3 ELISA Kits) uncoupling in the sickle cell penis which restores endothelial NO synthesis.
Data indicate that the phosphodiesterase 5 (PDE5) expression is equal in the splenocytes from both genders, but splenocytes from female mice possess higher basal level of cGMP compared to the male ones.
PDE5 inhibition did not alter atrial natriuretic peptide (show NPPA ELISA Kits)-stimulated cGMP in the resting heart but augmented it in the transaortic constriction heart.
Sildenafil-mediated PDE5 inhibition significantly reduces diaphragm respiratory muscle dysfunction and pathology in the mdx (show DMD ELISA Kits) mouse model of Duchenne muscular dystrophy (show DMD ELISA Kits).
PDE5 inhibition and increase in cGMP produce pulmonary vasodilation that is mediated in part through inhibition of the ET pathway, thereby precluding an additional vasodilator effect of ETA/ETB (show EDNRB ELISA Kits) receptor blockade in the presence of PDE5 inhibition.
PDE5 is a key regulator of NO-induced vasodilation in the postnatal pulmonary arteries.
This gene encodes a cGMP-binding, cGMP-specific phosphodiesterase, a member of the cyclic nucleotide phosphodiesterase family. This phosphodiesterase specifically hydrolyzes cGMP to 5'-GMP. It is involved in the regulation of intracellular concentrations of cyclic nucleotides and is important for smooth muscle relaxation in the cardiovascular system. Alternative splicing of this gene results in three transcript variants encoding distinct isoforms.
cGMP-binding cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase
, cGMP-specific 3',5'-cyclic phosphodiesterase
, cGMP-specific phosphodiesterase PDE5A2
, cGMP-specific phosphodiesterase type 5A
, phosphodiesterase isozyme 5
, cGMP-binding cGMP specific phosphodiesterase 5A2
, cGMP-binding cGMP-specific phosphodiesterase
, phosphodiesterase type 5
, cGMP-binding/cGMP-specific phosphodiesterase
, 3',5'-Cyclic GMP Phosphodiesterase
, phosphodiesterase 5A, cGMP-specific
, phosphodiesterase 5a, cGMP-specific
, phosphodiesterase 5a
, cGMP-specific 3',5'-cyclic phosphodiesterase-like
, cyclic nucleotide phosphodiesterase 5a